Increased RBI abnormalities in human primary prostate cancer following combined androgen blockade

Philip C. Mack, Sung-Gil Chi, Frederick J. Meyers, Susan L. Stewart, Ralph W. DeVere White, Paul H. Gumerlock

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

BACKGROUND. The RB1 proliferation control pathway is a critical determinant of cell cycle progression. Abnormalities of RB1 are found in a variety of cancers, and the association with human prostate cancer (CAP) was examined here. METHODS. RNA expression levels of RB1 in CaPs were examined by RT-PCR. RNA integrity was assessed by evaluating expression of an endogenous gene standard. RESULTS. Abnormally low RB1 mRNA expression was found in 12/33 (36%) of CaPs from patients who had received combined androgen blockade (CAB) treatment. In contrast, 6/48 (13%) untreated CaPs showed abnormally low expression. This difference was statistically significant (P = 0.015). In the samples from untreated patients, a higher frequency of abnormal RB1 was found in specimens with a higher Gleason grade (P = 0.038). In addition, one untreated stage C, grade 9 specimen was found to express RB1 transcripts lacking exon 22, as determined by sequencing of DNA from the truncated transcripts. CONCLUSIONS. These findings suggest that abnormalities of RB1 may contribute to hormone-withdrawal-related survival of CaP cells.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalProstate
Volume34
Issue number2
DOIs
Publication statusPublished - 1998 Feb 1
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
RNA
DNA Sequence Analysis
Exons
Cell Survival
Cell Cycle
Hormones
Gene Expression
Polymerase Chain Reaction
Messenger RNA
Neoplasms
Therapeutics

Keywords

  • Androgen ablation
  • CaP
  • RB1
  • RT-PCR

ASJC Scopus subject areas

  • Urology

Cite this

Increased RBI abnormalities in human primary prostate cancer following combined androgen blockade. / Mack, Philip C.; Chi, Sung-Gil; Meyers, Frederick J.; Stewart, Susan L.; DeVere White, Ralph W.; Gumerlock, Paul H.

In: Prostate, Vol. 34, No. 2, 01.02.1998, p. 145-151.

Research output: Contribution to journalArticle

Mack, Philip C. ; Chi, Sung-Gil ; Meyers, Frederick J. ; Stewart, Susan L. ; DeVere White, Ralph W. ; Gumerlock, Paul H. / Increased RBI abnormalities in human primary prostate cancer following combined androgen blockade. In: Prostate. 1998 ; Vol. 34, No. 2. pp. 145-151.
@article{ce6fb18680fd4c63bd34ec04d26e55bd,
title = "Increased RBI abnormalities in human primary prostate cancer following combined androgen blockade",
abstract = "BACKGROUND. The RB1 proliferation control pathway is a critical determinant of cell cycle progression. Abnormalities of RB1 are found in a variety of cancers, and the association with human prostate cancer (CAP) was examined here. METHODS. RNA expression levels of RB1 in CaPs were examined by RT-PCR. RNA integrity was assessed by evaluating expression of an endogenous gene standard. RESULTS. Abnormally low RB1 mRNA expression was found in 12/33 (36{\%}) of CaPs from patients who had received combined androgen blockade (CAB) treatment. In contrast, 6/48 (13{\%}) untreated CaPs showed abnormally low expression. This difference was statistically significant (P = 0.015). In the samples from untreated patients, a higher frequency of abnormal RB1 was found in specimens with a higher Gleason grade (P = 0.038). In addition, one untreated stage C, grade 9 specimen was found to express RB1 transcripts lacking exon 22, as determined by sequencing of DNA from the truncated transcripts. CONCLUSIONS. These findings suggest that abnormalities of RB1 may contribute to hormone-withdrawal-related survival of CaP cells.",
keywords = "Androgen ablation, CaP, RB1, RT-PCR",
author = "Mack, {Philip C.} and Sung-Gil Chi and Meyers, {Frederick J.} and Stewart, {Susan L.} and {DeVere White}, {Ralph W.} and Gumerlock, {Paul H.}",
year = "1998",
month = "2",
day = "1",
doi = "10.1002/(SICI)1097-0045(19980201)34:2<145::AID-PROS10>3.0.CO;2-I",
language = "English",
volume = "34",
pages = "145--151",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Increased RBI abnormalities in human primary prostate cancer following combined androgen blockade

AU - Mack, Philip C.

AU - Chi, Sung-Gil

AU - Meyers, Frederick J.

AU - Stewart, Susan L.

AU - DeVere White, Ralph W.

AU - Gumerlock, Paul H.

PY - 1998/2/1

Y1 - 1998/2/1

N2 - BACKGROUND. The RB1 proliferation control pathway is a critical determinant of cell cycle progression. Abnormalities of RB1 are found in a variety of cancers, and the association with human prostate cancer (CAP) was examined here. METHODS. RNA expression levels of RB1 in CaPs were examined by RT-PCR. RNA integrity was assessed by evaluating expression of an endogenous gene standard. RESULTS. Abnormally low RB1 mRNA expression was found in 12/33 (36%) of CaPs from patients who had received combined androgen blockade (CAB) treatment. In contrast, 6/48 (13%) untreated CaPs showed abnormally low expression. This difference was statistically significant (P = 0.015). In the samples from untreated patients, a higher frequency of abnormal RB1 was found in specimens with a higher Gleason grade (P = 0.038). In addition, one untreated stage C, grade 9 specimen was found to express RB1 transcripts lacking exon 22, as determined by sequencing of DNA from the truncated transcripts. CONCLUSIONS. These findings suggest that abnormalities of RB1 may contribute to hormone-withdrawal-related survival of CaP cells.

AB - BACKGROUND. The RB1 proliferation control pathway is a critical determinant of cell cycle progression. Abnormalities of RB1 are found in a variety of cancers, and the association with human prostate cancer (CAP) was examined here. METHODS. RNA expression levels of RB1 in CaPs were examined by RT-PCR. RNA integrity was assessed by evaluating expression of an endogenous gene standard. RESULTS. Abnormally low RB1 mRNA expression was found in 12/33 (36%) of CaPs from patients who had received combined androgen blockade (CAB) treatment. In contrast, 6/48 (13%) untreated CaPs showed abnormally low expression. This difference was statistically significant (P = 0.015). In the samples from untreated patients, a higher frequency of abnormal RB1 was found in specimens with a higher Gleason grade (P = 0.038). In addition, one untreated stage C, grade 9 specimen was found to express RB1 transcripts lacking exon 22, as determined by sequencing of DNA from the truncated transcripts. CONCLUSIONS. These findings suggest that abnormalities of RB1 may contribute to hormone-withdrawal-related survival of CaP cells.

KW - Androgen ablation

KW - CaP

KW - RB1

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=0031594514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031594514&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0045(19980201)34:2<145::AID-PROS10>3.0.CO;2-I

DO - 10.1002/(SICI)1097-0045(19980201)34:2<145::AID-PROS10>3.0.CO;2-I

M3 - Article

VL - 34

SP - 145

EP - 151

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 2

ER -